Priorities for improving drug research, development and regulation

Nature Reviews Drug Discovery

Volumn 12, Issue 4, 2013, Pages 247-248

  Forda, Susan R ^a,b   Bergström, Richard ^c   Chlebus, Magda ^c   Barker, Richard ^d   Andersen, Peter Høngaard ^e  

^a Scientific Regulatory and Manufacturing Policy Committee   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c EFPIA   (Belgium)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); COST CONTROL; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESEARCH; EUROPE; GOVERNMENT REGULATION; INTERNATIONAL COOPERATION; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REIMBURSEMENT; RESEARCH PRIORITY; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; STUDY DESIGN;

DRUG DESIGN; DRUG INDUSTRY; EUROPE; HUMANS; MODELS, ORGANIZATIONAL; RESEARCH;

EID: 84875708585     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3981     Document Type: Review

References (4)

1. Kola, I. & Bell. J. Nature Rev. Drug Discov. 10, 641-642 (2011).
2. Orloff, J. et al. Nature Rev. Drug Discov. 8, 949-957 (2009).
3. Breckenridge, A. et al. Nature Rev. Drug Discov. 11, 501-502 (2012).
4. European Medicines Agency (EMA) [online], http://www.ema.europa.eu/docs/ en-GB/document-library/Report/2011/01/WC500101373.pdf (2010).